Adults aged 23-57 years. Patients meeting the 2010 American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) classification criteria for rheumatoid arthritis (RA).
Patients with active RA, regardless of disease duration. Patients receiving stable doses of permitted concomitant medications, including: Methotrexate (MTX), Nonsteroidal anti-inflammatory drugs (NSAIDs), Selective cyclooxygenase-2 (COX-2) inhibitors, Acetaminophen, and Low-dose oral corticosteroids.
Patients stabilized on combination conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for more than four weeks will be eligible for inclusion.
You may not be if
Use of intravenous, intra-articular, or intramuscular corticosteroids within four weeks before initiation of the study medication.
Use of intra-articular sodium hyaluronate within four weeks before initiation of the study medication.
Use of biologic disease-modifying antirheumatic drugs (bDMARDs) within four weeks before initiation of the study medication.
Initiation or use of additional csDMARDs within four weeks before initiation of the study medication, except for patients stabilized on combination csDMARD therapy for more than four weeks.
